OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Richardson Discusses the Results of the OPTIMISMM Trial in Myeloma

June 23rd 2018

Paul Richardson, MD, clinical program leader, director of Clinical Research, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, RJ Corman Professor of Medicine, Harvard Medical School, discusses the results of the OPTIMISMM trial in patients with multiple myeloma.

Dr. Novik on the Adoption of Biosimilars in Breast Cancer

June 23rd 2018

Yelena Novik, MD, associate professor, Department of Medicine, New York University’s Perlmutter Cancer Center, discusses the adoption of biosimilars in breast cancer.

Dr. Pecora on the Role of Stem Cell Transplant in Patients With Multiple Myeloma

June 23rd 2018

Andrew L. Pecora, MD, president of the Physician Services Division and chief innovation officer at Hackensack Meridian Health, discusses the role of stem cell transplant in patients with multiple myeloma.

Dr. Glaspy on Immunotherapy in Endometrial Cancer

June 23rd 2018

John A. Glaspy, MD, professor of medicine, Jonsson Comprehensive Cancer Center (JCCC), director, JCCC Clinical Research Unit and Women's Cancer Research Program, University of California, Los Angeles School of Medicine, discusses immunogenicity in endometrial cancer.

Dr. Goy on Prognostic Markers in Mantle Cell Lymphoma

June 22nd 2018

Andre Goy, MD, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses prognostic markers in mantle cell lymphoma (MCL).

Dr. Wingo on the Evolution of Surgery in Endometrial Cancer

June 22nd 2018

Shana Wingo, MD, gynecologic oncologist, Arizona Oncology, discusses the evolution of surgery in endometrial cancer.

Dr. Ali on the Future of Adjuvant Care for HER2+ Breast Cancer

June 21st 2018

Haythem Y. Ali, MD, senior medical oncologist, Henry Ford Hospital, discusses the future of adjuvant treatment for patients with HER2-positive breast cancer.

Dr. Ferris Discusses Nivolumab in Head and Neck Cancer

June 21st 2018

Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and co-leader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, discusses nivolumab (Opdivo) in the treatment of patients with head and neck cancer.

Dr. Ascierto on the COLUMBUS Trial in Melanoma

June 21st 2018

Paolo A. Ascierto, MD, director of the Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy at the National Tumor Institute Fondazione G. Pascale in Naples, discusses the COLUMBUS trial in melanoma.

Dr. Kolberg Discusses the Central Pathology Review of ABP 980

June 21st 2018

Hans-Christian Kolberg, MD, head, Department of Obstetrics and Gynecology, Breast Cancer Center, and Gynecologic Cancer Center at Marienhospital Bottrop, Klinik für Gynäkologie und Geburtshilfe, Bottrop, Germany, discusses the central pathology review of the trastuzumab (Herceptin) biosimilar ABP 980.

Dr. Borchmann Discusses the Updated Analysis of JULIET in DLBCL

June 21st 2018

Peter Borchmann, MD, professor, University Hospital of Cologne, Cologne, Germany, discusses the updated analysis of the JULIET trial in patients with diffuse large B-cell lymphoma (DLBCL).

Dr. Husain on Plasma-Based Testing in Lung Cancer

June 20th 2018

Hatim Husain, MD, assistant professor of Medicine, Moores Cancer Center, University of California, San Diego, discusses plasma-based testing in lung cancer.

Dr. Rini Discusses Atezolizumab Plus Bevacizumab in RCC

June 20th 2018

Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses atezolizumab (Tecentriq) plus bevacizumab (Avastin) in renal cell carcinoma.

Dr. Davids Discusses Duvelisib in Relapsed/Refractory CLL

June 20th 2018

Matthew S. Davids, MD, MMSc, associate director, Center for Chronic Lymphocytic Leukemia, Dana-Farber Cancer Institute, discusses duvelisib in relapsed/refractory chronic lymphocytic leukemia.

Dr. Mitri on Neratinib and Pertuzumab in HER2-Amplified Breast Cancer

June 19th 2018

Zahi Mitri, MD, MS, assistant professor of medicine, Oregon Health and Science University, discusses the use of neratinib (Nerlynx) and pertuzumab (Perjeta) in patients with HER2-amplified breast cancer.

Dr. Grivas on Immunotherapy in Advanced Urothelial Cancer

June 19th 2018

Petros Grivas, MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program, associate professor, Oncology, University of Washington, Seattle Cancer Care Alliance, discusses the use of immunotherapy in patients with advanced urothelial cancer.

Dr. Wirth on the Use of Lenvatinib in Hypertensive Patients With Thyroid Cancer

June 18th 2018

Lori J. Wirth, MD, associate professor, Medicine, Harvard Medical School, medical director, Center for Head and Neck Cancers, Massachusetts General Hospital, discusses the use of lenvatinib in hypertensive patients with thyroid cancer.

Dr. Singh on the Use of Chemotherapy in Patients With Uterine Leiomyosarcomas

June 18th 2018

Arun S. Singh, MD, associate professor, Department of Medicine, Division of Hematology/Oncology, University of California, Los Angeles, discusses the use of chemotherapy in patients with uterine leiomyosarcomas.

Dr. Bekaii-Saab on Immunotherapy in Colorectal Cancer

June 18th 2018

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the use of immunotherapy in patients with microsatellite stable colorectal cancer.

Dr. Savin on the Evolution of Biosimilars

June 16th 2018

Michael A. Savin, MD, assistant professor of medicine, School of Medicine, Oregon Health and Science University, discusses the evolution of biosimilars.